548 related articles for article (PubMed ID: 12017404)
1. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
2. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
Cazzola M; Santus P; Matera MG; Carlucci P; Belloli E; Di Marco F; Centanni S
Respir Med; 2003 May; 97(5):458-62. PubMed ID: 12735660
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
[TBL] [Abstract][Full Text] [Related]
5. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.
Cazzola M; Centanni S; Regorda C; di Marco F; di Perna F; Carlucci P; Boveri B; Santus P
Pulm Pharmacol Ther; 2001; 14(1):41-5. PubMed ID: 11162418
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD.
Cazzola M; Califano C; Di Perna F; D'Amato M; Terzano C; Matera MG; D'Amato G; Marsico SA
Respir Med; 2002 Oct; 96(10):790-5. PubMed ID: 12412978
[TBL] [Abstract][Full Text] [Related]
7. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
[TBL] [Abstract][Full Text] [Related]
8. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD.
Cazzola M; Di Perna F; D'Amato M; Califano C; Matera MG; D'Amato G
Respir Med; 2001 Nov; 95(11):917-21. PubMed ID: 11716207
[TBL] [Abstract][Full Text] [Related]
9. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI.
Seberová E; Andersson A
Respir Med; 2000 Jun; 94(6):607-11. PubMed ID: 10921767
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
12. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.
Boonsawat W; Charoenratanakul S; Pothirat C; Sawanyawisuth K; Seearamroongruang T; Bengtsson T; Brander R; Selroos O
Respir Med; 2003 Sep; 97(9):1067-74. PubMed ID: 14509562
[TBL] [Abstract][Full Text] [Related]
13. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
14. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
15. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
Pleskow W; LaForce CF; Yegen U; Matos D; Della Cioppa G
J Asthma; 2003; 40(5):505-14. PubMed ID: 14529100
[TBL] [Abstract][Full Text] [Related]
16. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Brambilla C; Le Gros V; Bourdeix I;
Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the bronchodilatory effect of 50 and 100 microg salbutamol via Turbuhaler and 100 microg salbutamol via pressurized metered dose inhaler in children with stable asthma.
Razzouk H; dos Santos L; Giudicelli J; Queirós M; de Lurdes Chieira M; Castro A; Ramos C; Lindbladh C
Int J Pharm; 1999 Apr; 180(2):169-75. PubMed ID: 10370187
[TBL] [Abstract][Full Text] [Related]
18. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
19. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.
La Piana GE; Corda L; Bertella E; Montemurro LT; Pini L; Tantucci C
Int J Chron Obstruct Pulmon Dis; 2011; 6():399-405. PubMed ID: 21857779
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
